Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer

Bauer, Katrina; Parise, Carol; Caggiano, Vincent
January 2010
BMC Cancer;2010, Vol. 10, p228
Academic Journal
Background: The 2007 St Gallen international expert consensus statement describes three risk categories and provides recommendations for treatment of early breast cancer. The set of recommendations on how to best treat primary breast cancer is recognized and used by clinicians worldwide. We now examine the variability of five-year survival of the 2007 St Gallen Risk Classifications utilizing the ER/PR/HER2 subtypes. Methods: Using the population-based California Cancer Registry, 114,786 incident cases of Stages 1-3 invasive breast cancer diagnosed between 2000 and 2006 were identified. Cases were assigned to Low, Intermediate, or High Risk categories. Five-year-relative survival was computed for the three St Gallen risk categories and for the ER/PR/HER2 subtypes for further differentiation. Results and Discussion: There were 9,124 (13%) cases classified as Low Risk, 44,234 (65%) cases as Intermediate Risk, and 14,340 (21%) as High Risk. Within the Intermediate Risk group, 33,735 (76%) were node-negative (Intermediate Risk 2) and 10,499 (24%) were node-positive (Intermediate Risk 3). For the High Risk group, 6,149 (43%) had 1 to 3 positive axillary lymph nodes (High Risk 4) and 8,191 (57%) had four or more positive lymph nodes (High Risk 5). Using five-year relative survival as the principal criterion, we found the following: a) There was very little difference between the Low Risk and Intermediate Risk categories; b) Use of the ER/PR/HER2 subtypes within the Intermediate and High Risk categories separated each into a group with better five-year survival (ER-positive) and a group with worse survival (ER-negative), irrespective of HER2-status; c) The heterogeneity of the High Risk category was most evident when one examined the ER/PR/HER2 subtypes with four or more positive axillary lymph nodes; (d) HER2- positivity did not always translate to worse survival, as noted when one compared the triple positive subtype (ER+/ PR+/HER2+) to the triple negative subtype (ER-/PR-/HER2-); and (e) ER-negativity appeared to be a stronger predictor of poor survival than HER2-positivity. Conclusion: The use of ER/PR/HER2 subtype highlights the marked heterogeneity of the Intermediate and High Risk categories of the 2007 St Gallen statements. The use of ER/PR/HER2 subtypes and correlation with molecular classification of breast cancer is recommended.


Related Articles

  • Uloga detekcije sentinel limfonoda u menadžmentu pacijenata sa karcinomom dojke. Bešlić, Nermina // Medicinski Arhiv;2008, Vol. 62 Issue 4, p240 

    One of the possible ways breast cancer can spread is by lymphatic system. The first lymph node to be affected is called sentinel node (SLN) and can be identified by injecting radioactive tracer. During sentinel lymph node biopsy, the node is located by hand held probe. The result of frozen...

  • Detection of the sentinel lymph node in breast cancer. Santosh K. Somasundaram; Dennis W. Chicken; Mohammed R. S. Keshtgar // British Medical Bulletin;Dec2007, Vol. 84 Issue 1, p117 

    Introduction Introduction: Axillary lymph node status for lymphatic staging in breast cancer is the best prognostic indicator and guides systemic treatment. Sentinel lymph node (SLN) biopsy is a novel, minimally invasive technique for lymphatic staging proven to improve quality of life. The...

  • Axillary lymph node dissection for breast cancer utilizing Harmonic Focus.  // World Journal of Surgical Oncology;2011, Vol. 9 Issue 1, p90 

    The article focuses on a research study related to the axillary lymph node dissection (ALND) for breast cancer. Retrospective review identified all patients who underwent ALND at a teaching hospital between January of 2005 and December of 2009. Patient demographics, presenting pathology,...

  • Lymphatic and Angiogenic Candidate Genes Predict the Development of Secondary Lymphedema following Breast Cancer Surgery. Miaskowski, Christine; Dodd, Marylin; Paul, Steven M.; West, Claudia; Hamolsky, Deborah; Abrams, Gary; Cooper, Bruce A.; Elboim, Charles; Neuhaus, John; Schmidt, Brian L.; Smoot, Betty; Aouizerat, Bradley E. // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    The purposes of this study were to evaluate for differences in phenotypic and genotypic characteristics in women who did and did not develop lymphedema (LE) following breast cancer treatment. Breast cancer patients completed a number of self-report questionnaires. LE was evaluated using...

  • Sentinel Lymph Node Biopsy for Breast Cancer: Our Technique and Future Directions in Lymph Node Staging. Rashid, Omar M.; Takabe, Kazuaki // Journal of Nuclear Medicine & Radiation Therapy;2012 Supplement 2, p1 

    Breast cancer remains a major cause of cancer death for women in the United States. Accurate cancer staging, especially of the axillary lymph nodes, is essential for predicting the prognosis of patients and for determining the appropriate multimodality treatment strategy. Historically, the...

  • Intensive treatment of post-breast cancer upper limb lymphedema. Buzato, Edivandra; Santana, Cassio Gustavo; Lopes, Karina Paludetto // Journal of Phlebology & Lymphology;2012, Vol. 5, p14 

    This paper describes a case of intensive treatment for the volumetric reduction of upper limb lymphedema. A 65-year-old female developed lymphedema of the right upper limb following breast cancer treatment, with a six-year history. A burn on the right upper arm and an episode of erysipelas in...

  • Sentinel Lymph Node Biopsy in the Management of Breast Cancer. Kumar, R.; Bozkurt, M.F.; Zhuang, H.; Alavi, A. // Indian Journal of Cancer;Apr2003, Vol. 40 Issue 2, p60 

    Sentinel node localization is the second most important development in this century after conservative lumpectomy for the treatment of early breast cancer. The sentinel node mapping is a new multidisciplinary approach for staging of axilla in an accurate and less morbid way as compared to...

  • Sentinel node biopsy for early oral and oropharyngeal squamous cell carcinoma. Stoeckli, Sandro J.; Alkureishi, Lee W. T.; Ross, Gary L. // European Archives of Oto-Rhino-Laryngology;Jun2009, Vol. 266 Issue 6, p787 

    The appearance of lymph node metastases represents the most important adverse prognostic factor in head and neck squamous cell carcinoma. Therefore, accurate staging of the cervical nodes is crucial in these patients. The management of the clinically and radiologically negative neck in patients...

  • Sentinel Lymph Node Biopsy is a Reliable Method for Lymph Node Evaluation in Neoadjuvant Chemotherapy-treated Patients with Breast Cancer. KOSLOW, STARR B.; EISENBERG, RACHEL E. K.; QIU, QUEENIE; ZHENGMING CHEN; SWISTEL, ALEXANDER; SHIN, SANDRA J. // American Surgeon;Feb2014, Vol. 80 Issue 2, p171 

    Sentinel lymph node (SLN) mapping in patients with breast cancer treated with neoadjuvant chemotherapy has been debated by surgeons as a result of potential compromise of lymphatic drainage. Whether clinicopathologic variables traditionally associated with SLN positivity differ in patients who...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics